A point, a line, or an area? Which is the most important in the pharmacological analysis of cancer chemotherapy?

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 405-406

  Minami, Hironobu ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; DOCETAXEL; EPIRUBICIN; TOPOTECAN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CELL MATURATION; CELL PROLIFERATION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MONITORING; EDITORIAL; HUMAN; LEUKOPENIA; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; CHEMICALLY INDUCED DISORDER; MONITORING; NEOPLASM; NOTE; THEORETICAL MODEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKOPENIA; MODELS, THEORETICAL; MONITORING, PHYSIOLOGIC; NEOPLASMS;

EID: 14544285508     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.905     Document Type: Editorial

References (10)

1. Ratain MJ, Schilsky RL, Conley BA, et al: Pharmacodynamics in cancer therapy. J Clin Oncol 8:1739-1753, 1990
2. Sandström M, Lindman H, Nygren P, et al: A model describing the relationship between pharmacokinetics and hematological toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23:413-421, 2005
3. Friberg LE, Henningsson A, Maas H, et al: Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-4721, 2002
4. Karlsson MO, Port RE, Ratain MJ, et al: A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 57:325-334, 1995
5. Karlsson MO, Molnar V, Bergh J, et al: A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63:11-25, 1998
6. Minami H, Sasaki Y, Saijo N, et al: Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64:511-521, 1998
7. Zamboni W, D'Argenio DZ, Stewart CF, et al: Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res 7:2301-2308, 2001
8. Minami H, Sasaki Y, Watanabe T, et al: Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel. Jpn J Cancer Res 92:231-238, 2001
9. Ando Y, Minami H, Saka H, et al: Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer. Jpn J Cancer Res 87:200-205, 1996
10. Ando Y, Minami H, Saka H, et al: Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer. Jpn J Cancer Res 87:856- 861, 1996